About us

Building on more than a decade of research to address unmet medical needs

Mission

We aim to develop treatment options for those diseases that have an impact on all our lives and directly benefit patients' survival and overall quality of life.

Recent Highlights

2018

Following a publication in the PNAS, the Federal German Ministry for Education and Research backs PROSION Therapeutics' research with a €1m grant for the in-vivo validation of Ena/VASP as target proteins for metastatic cancer therapy.

2020

The Federal German Ministry for Economics and Technology backs the translation of the cutting-edge research into a biotech company through its EXIST programme - founding of PROSION GmbH follows by the end of 2020.

2021

PROSION Therapeutics secures a €2.5m (non-dilutive) grant from the highly competitive European Innovation Council (EIC) Accelerator for the deployment of its platform technology and to further boost its lead program in oncology.

2022

PROSION Therapeutics secures Seed Investment from renowned early-stage Deep-Tech investor Freigeist Capital to further accelerate the deployment of its platform technology and lead program in oncology.

2023

PROSION Therapeutics is eligible for an equity co-investment of up to €15m from the European Investment Bank (EIB).

Our team

Meet the team - a strong mixture of scientists and professionals - and our highly experienced advisors.

Team Members

Dr. Slim Chiha

Co-Founder & CEO

Mutlu Yönel

Co-Founder & CFO

Dr. Jürgen Beck

CMO

Dr. Matthias Müller

Head of Biochemistry

Dr. Dominik Albat

Head of Chemistry

Juliana Rojas Pion

Research Associate Biology

Dr. Luigi La Pietra

Lead Preclinical Development

Greta Schmidt

Associate

Emma Lemeunier

Research Associate Chemistry

“PROSION Therapeutics’ approach represents an elegant way to develop entirely novel drugs with game-changing potential.”

— Dr. Franz von Nussbaum

Advisors

Prof. Dr. Hans-Günther Schmalz is an expert in stereoselective and total synthesis. As a professor for Organic Chemistry at the University of Cologne, he initiated the academic research behind the ProM-approach together with Dr. Kühne.

Prof. Dr. H.-G. Schmalz

Co-Founder & Scientific Advisor

Dr. Ronald Kühne is a highly experienced professional in Computational Chemistry and Drug Design. As the Head of Drug Design at the FMP in Berlin, he initiated the academic research behind the ProM-approach together with Prof. Dr. H.-G. Schmalz.

Dr. Ronald Kühne

Co-Founder & Scientific Advisor

Dr. Franz von Nussbaum is a highly experienced MedChemist, with more than 20 years of experience in medicinal chemistry. He is the former VP Life Science Chemistry at Bayer AG and the current Executive VP at Nuvisan ICB.

Dr. Franz von Nussbaum

Scientific Advisor

Professor Rainer Metternich is a Senior Executive (and former board member at Schering AG) with more than 30 years experience at global pharmaceutical companies and biotechs.

Prof. Dr. Rainer Metternich

Scientific Advisor

Professor Peter ten Dijke is a researcher and professor at Leiden University in the Netherlands. He is a distinguished expert in the field of molecular and cellular biology, with a focus on the regulation of gene expression and signaling pathways.

Prof. Dr. Peter ten Dijke

Scientific Advisor

Our partners

We are proud to work with a number of investors and institutes, who support us on this important mission.

Excited about our mission?

Reach out to us